In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Regenxbio Inc (NASDAQ: RGNX) closed at $11.21 in the last session, up 0.36% from day before closing price of $11.17. In other words, the price has increased by $0.36 from its previous closing price. On the day, 0.62 million shares were traded. RGNX stock price reached its highest trading level at $11.335 during the session, while it also had its lowest trading level at $10.81.
Ratios:
We take a closer look at RGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.66 and its Current Ratio is at 2.66. In the meantime, Its Debt-to-Equity ratio is 1.66 whereas as Long-Term Debt/Eq ratio is at 1.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 09 ’25 when Simpson Curran sold 20,811 shares for $12.62 per share. The transaction valued at 262,635 led to the insider holds 216,162 shares of the business.
CURRAN M SIMPSON bought 20,811 shares of RGNX for $254,310 on Oct 09 ’25. On Sep 29 ’25, another insider, Simpson Curran, who serves as the Chief Executive Officer of the company, sold 7,624 shares for $10.03 each. As a result, the insider received 76,469 and left with 236,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 567484800 and an Enterprise Value of 561419776. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.52 while its Price-to-Book (P/B) ratio in mrq is 3.51. Its current Enterprise Value per Revenue stands at 3.48 whereas that against EBITDA is -4.034.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.17, which has changed by -0.030276835 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $13.93, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 4.01%, while the 200-Day Moving Average is calculated to be 27.64%.
Shares Statistics:
According to the various share statistics, RGNX traded on average about 603.51K shares per day over the past 3-months and 559910 shares per day over the past 10 days. A total of 50.62M shares are outstanding, with a floating share count of 46.27M. Insiders hold about 8.59% of the company’s shares, while institutions hold 83.45% stake in the company. Shares short for RGNX as of 1760486400 were 4880756 with a Short Ratio of 8.09, compared to 1757894400 on 5066044. Therefore, it implies a Short% of Shares Outstanding of 4880756 and a Short% of Float of 11.73.
Earnings Estimates
The firm’s stock currently is rated by 7.0 analysts. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.19 and low estimates of -$1.58.
Analysts are recommending an EPS of between -$1.67 and -$4.11 for the fiscal current year, implying an average EPS of -$3.2. EPS for the following year is -$2.46, with 7.0 analysts recommending between $1.43 and -$5.22.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $59.92M. It ranges from a high estimate of $140M to a low estimate of $23.7M. As of. The current estimate, Regenxbio Inc’s year-ago sales were $21.21MFor the next quarter, 6 analysts are estimating revenue of $77.53M. There is a high estimate of $276.57M for the next quarter, whereas the lowest estimate is $21M.
A total of 7 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $280M, while the lowest revenue estimate was $163.8M, resulting in an average revenue estimate of $198.61M. In the same quarter a year ago, actual revenue was $83.33MBased on 10 analysts’ estimates, the company’s revenue will be $274.37M in the next fiscal year. The high estimate is $407.6M and the low estimate is $140.63M.
